Ligand Pharmaceuticals Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ligand Pharmaceuticals stock.
View analyst ratings for Ligand Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Ligand Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ligand Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Ligand Pharmaceuticals.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its quarterly earnings data on Sunday, May, 2nd. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.13 by $0.28. The biotechnology company had revenue of $55.10 million for the quarter, compared to analysts' expectations of $63 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 8.50% and a net margin of 18.83%. The business's revenue was up 66.0% on a year-over-year basis. During the same quarter last year, the company posted $0.89 EPS.
View Ligand Pharmaceuticals' earnings history.

Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LGND shares have increased by 34.6% and is now trading at $123.63.
View which stocks have been most impacted by COVID-19.

Ligand Pharmaceuticals updated its FY 2021 earnings guidance on Monday, May, 17th. The company provided EPS guidance of 6.150-6.150 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.170. The company issued revenue guidance of $291 million-$291 million, compared to the consensus revenue estimate of $291.62 million.

7 brokerages have issued 1-year target prices for Ligand Pharmaceuticals' stock. Their forecasts range from $155.00 to $310.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $214.00 in the next twelve months. This suggests a possible upside of 73.1% from the stock's current price.
View analysts' price targets for Ligand Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated Ligand Pharmaceuticals CEO John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among Ligand Pharmaceuticals' employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of LGND's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include William Blair Investment Management LLC (7.75%), Janus Henderson Group PLC (7.55%), Villere ST Denis J & Co. LLC (3.23%), Conestoga Capital Advisors LLC (2.99%), Chicago Capital LLC (2.70%) and Kornitzer Capital Management Inc. KS (2.43%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, Matthew W Foehr, Sunil Patel and Todd C Davis.
View institutional ownership trends for Ligand Pharmaceuticals.

LGND stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., JPMorgan Chase & Co., Wasatch Advisors Inc., William Blair Investment Management LLC, Janus Henderson Group PLC, Eaton Vance Management, Conestoga Capital Advisors LLC, and Stephens Investment Management Group LLC. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, John L Higgins, Matthew W Foehr, and Todd C Davis.
View insider buying and selling activity for Ligand Pharmaceuticals or view top insider-selling stocks.

LGND stock was acquired by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Voloridge Investment Management LLC, Victory Capital Management Inc., Geode Capital Management LLC, Penserra Capital Management LLC, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, Principal Financial Group Inc., and Principal Financial Group Inc.. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins, Matthew W Foehr, and Sunil Patel.
View insider buying and selling activity for Ligand Pharmaceuticals or or view top insider-buying stocks.

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LGND stock can currently be purchased for approximately $123.63.

Ligand Pharmaceuticals has a market capitalization of $2.06 billion and generates $186.42 million in revenue each year. The biotechnology company earns $-2,980,000.00 in net income (profit) each year or $3.13 on an earnings per share basis.

Ligand Pharmaceuticals employs 155 workers across the globe.

The official website for Ligand Pharmaceuticals is www.ligand.com.

Ligand Pharmaceuticals is headquartered at 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]